Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

COMPARE StudyThe COMPARE study is a physician-initiated "all-comers" trial sponsored by Maasstad Ziekenhuis of Rotterdam, the Netherlands. The study, designed to reflect real-world, everyday clinical practice, enrolled 1,800 patients in a single- center, prospective randomized (1:1) comparison of safety and efficacy of the XIENCE V™ Everolimus Eluting Stent System to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System.  The COMPARE trial was supported in part by an Abbott grant.  All aspects of the trial were designed and conducted independent of Abbott.

About XIENCE VAbbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott VascularAbbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.<
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Concepts (SMEV.PK), the manufacturer and developer of medical, ... that the Company has signed a co-branding preferred vendor ... franchise offering Health Clubs and Weight Loss Centers for ... as Mexico and Canada, SE Concepts expects a long ...
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
Cached Medicine Technology:SpaCapsule Manufacturer Enters Preferred Vendor Agreement With Prominent Women's Fitness Franchise 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3
(Date:7/11/2014)... 11, 2014 The International Concussion ... at the Best Buy Theater in Times Square, ... to the growing concussion epidemic that is plaguing ... levels of competition. , The Symposium gathers more ... researchers, coaches, professional athletes and legal scholars for ...
(Date:7/11/2014)... Newport Beach, CA (PRWEB) July 11, 2014 ... product pure Artichoke Leaf Extract dietary supplements to aid ... flow, an action necessary to facilitate metabolism of fat. ... facilities, Superior Labs Artichoke Leaf Extract is available in ... of pure artichoke extract. , Health Benefits of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... begin this August in New York. ... cover: , -Myofascial Trigger Point Therapy, ... -Mobilization & Thrust Manipulation, -Neuroobilization & Neurodynamics, ... prescribing to a single, isolated manual therapy ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 This morning(July 9th, ... 13--Good Morning Memphis to discuss the illegal immigration crisis at ... town of McAllen, Texas. , Dr. Flinn told Good Morning ... is absolutely wide open… The problem is that they do ... Thousands of people per day are coming into the border; ...
Breaking Medicine News(10 mins):Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 3Health News:Hands-On Seminars, the Leader in Manual Therapy Continuing Education, Announces Series of Comprehensive Hands-On Training Courses 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2
... developed deposits, study finds , , WEDNESDAY, Feb. 4 (HealthDay ... sickened more than 50,000 kids last fall resulted in ... developing kidney problems, according to just-released Beijing research on ... in Taiwan and 10 percent of those who drank ...
... (AUA) will hold its Annual Scientific Meeting in Chicago, ... Meeting is the largest meeting of urologic professionals in ... urologists and healthcare professionals from around the world. This ... more than 300 exhibitors will showcase their products and ...
... Pharmacies will host an in-store Healthy Heart Event., ... well as provide information to help patients better ... Pharmacists will also help patients, ... blood pressure and heart disease., WHY: ...
... /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: ... will be presenting at the National Cancer Institute,s Office ... series. The title of the presentation is "Selective Cytotoxic ... Effects in Patients with Advanced Breast Cancer," and will ...
... provider of complete solutions for the analysis of Next ... Molecular Biology Laboratory (EMBL) installed a Genomatix Mining Station ... Facility. These systems deliver the only complete and integrated ... generated by the sequencer, to a molecular level understanding ...
... is seeking nominations for the Fourth Annual Bioscience Awards ... interested in nominating a company or individual for an ... are: Entrepreneurial, Best New Product or Progress, Leadership in ... submit documentation and narratives that fulfill several criteria and ...
Cached Medicine News:Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 3Health News:Bionovo Announces Presentation at the National Cancer Institute 2Health News:Bionovo Announces Presentation at the National Cancer Institute 3Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 2Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 3Health News:GBC Seeks Nominations for Fourth Annual Bioscience Awards 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: